Choi Seong Hye, Shim YongSoo, Kim SangYun, Yang Dong Won, Park Kee Hyung, Kim JinRan, Youn Young Chul
Department of Neurology, College of Medicine, Inha University, Incheon, South Korea.
Department of Neurology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Dement Geriatr Cogn Dis Extra. 2025 Jun 10;15(1):99-107. doi: 10.1159/000546791. eCollection 2025 Jan-Dec.
Mild cognitive impairment (MCI) represents a loss of memory or other cognitive function while maintaining the ability to independently perform most activities of daily living. This study assessed how Korean specialists in dementia care diagnosed and treated patients with MCI symptoms.
A questionnaire on the current management of MCI was developed by 6 experts in MCI care. Specialists in MCI care ( = 24: 14 neurologists/10 psychiatrists) verbally answered questions relating to their experience/views in caring for MCI patients.
Respondents diagnosed MCI using the Seoul Neuropsychological Screening Battery (79%) and the Consortium to Establish a Registry for Alzheimer's Disease - Korea (21%) neuropsychological battery tests. All or nearly all respondents also assessed patients with Mini-Mental State Examination, Geriatric Depression Scale, Clinical Dementia Rating, Activities of Daily Living (ADL), and Instrumental ADL tests. All respondents used MRI or CT for differential diagnosis of diseases causing MCI, about one-third used amyloid PET. Most respondents (96%) treated patients with MCI due to Alzheimer's disease (AD) with medication, commonly choline alfoscerate (71%) and donepezil (53%), mainly as combination therapy. Unmet needs included patient/caregiver education (63%) and time constraints for consulting patients (54%). Most respondents considered that increased amyloid-β testing for patients with MCI due to AD or subjective cognitive decline is likely to increase.
This survey described the current management of MCI due to AD, identified unmet needs and considered possible future developments in the changing landscape of early AD treatment. Early detection and diagnosis and continued development of emerging preventative or therapeutic interventions are critical for MCI outcomes.
轻度认知障碍（MCI）表现为记忆力或其他认知功能丧失，同时仍保持独立进行大多数日常生活活动的能力。本研究评估了韩国痴呆症护理专家如何诊断和治疗有MCI症状的患者。
由6位MCI护理专家编制了一份关于MCI当前管理情况的问卷。MCI护理专家（n = 24：14名神经科医生/10名精神科医生）口头回答了与他们在护理MCI患者方面的经验/观点相关的问题。
受访者使用首尔神经心理筛查量表（79%）和韩国阿尔茨海默病注册协会神经心理量表（21%）诊断MCI。所有或几乎所有受访者还使用简易精神状态检查表、老年抑郁量表、临床痴呆评定量表、日常生活活动能力（ADL）和工具性ADL测试对患者进行评估。所有受访者使用MRI或CT对导致MCI的疾病进行鉴别诊断，约三分之一的受访者使用淀粉样蛋白PET。大多数受访者（96%）使用药物治疗因阿尔茨海默病（AD）导致的MCI患者，常用药物为阿法骨化醇胆碱（71%）和多奈哌齐（53%），主要作为联合治疗。未满足的需求包括患者/护理人员教育（63%）和咨询患者的时间限制（54%）。大多数受访者认为，对因AD或主观认知下降导致MCI的患者增加淀粉样蛋白-β检测的可能性会增加。
本调查描述了AD所致MCI的当前管理情况，确定了未满足的需求，并考虑了早期AD治疗不断变化的格局中可能的未来发展。早期检测和诊断以及新兴预防或治疗干预措施的持续发展对MCI的治疗结果至关重要。
